| Species | Cynomolgus | ||||
| Protein Construction |
|
||||
| Purity | > 95% as determined by BisTris PAGE | ||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Biological Activity | Measured by its binding ability in a functional ELISA.Test result was comparable to standard batch. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 39.47 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 60-68 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable for 6 months at -20℃ or below. Upon reconstitution, the product should be stable for 3 months at -80℃. Avoid repeated freeze-thaw cycles. |
Immobilized IL-18RAP/IL-18 R beta, His, Cynomolgus, His Tag at 0.2 μg /ml (100 μl /well) on the plate. Dose response curve for Anti-IL-18RAP Antibody, hFc Tag with the EC50 of 4.7ng/ml determined by ELISA. »
The purity of IL-18RAP/IL-18 R beta, His, Cynomolgus is greater than 95% as determined by SEC-HPLC. »
IL-18RAP/IL-18 R beta, His, Cynomolgus on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | IL-18RAP, also known as IL-18Rβ or IL-1R7, is component of IL-18 receptor complex and its interactions with IL-18R1 mediate signal transduction initiated by IL-18 although it does not directly bind IL-18 in vitro. |
| Synonyms | IL-18 R beta; ACPL; CD218b; CDw218b; IL-18R-beta; IL-18Rbeta; IL-18RAcP; IL-1R-7; IL-1R7; IL-1RAcPL; IL18RB; IL18RAP; IL-18R-beta; IL-18R-β; IL-18Rβ |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.